摘要
颅内血管支架置入已成为治疗颅内外动脉狭窄的主要方法之一,而支架置入后的一系列并发症,如血栓形成、颅内出血、支架内再狭窄等,越来越引起人们的关注。颅内外动脉支架置入后血管中层平滑肌迁移和增殖是导致内膜增生及支架内再狭窄的主要发病机制,而炎性反应和炎症因子在其中发挥重要作用。支架的材料学来源影响置入后支架内再狭窄的发生率。如药物支架表面涂有药物,当支架置入人体内后,药物能够持续高浓度的释放,达到有效治疗浓度,而且维持一定的释放时间,有效地预防支架内置入后的再狭窄,但其所释放的药物对脑组织是否安全还有待研究。因为,从血管支架材料学来源全面认识提高支架生物相容性,对防止支架置入后再狭窄的发生有着不可或缺的作用。
Intracranial vascular stenting has become one of the main methods for intracranial and extracranial arterial stenosis. The complications after stenting such as theombogenesis, intracranial hemorrhage, and in-stent stenosis have aroused more attention. After the stenting of intracranial and extracranial arteries, migration and proliferation of smooth muscle in vascular intercellular layer are the main pathogenesis of intimal hyperplasia and in-stent restenosis, and the inflammatory response and inflammatory factors play important roles in the process. The source of stent materials can affect the incidence of in-stent restenosis after stenting. After stenting of drug-eluting stent, the drug can be kept release of high concentration to reach the effective concentration for treatment, which can effectively prevent the restenosis after stenting. However, whether the released drug is safe to brain tissue still needs further study. Improving the biocompatibility of stents is one of the important means to prevent restenosis after stenting.
出处
《中国组织工程研究与临床康复》
CAS
CSCD
北大核心
2008年第22期4311-4314,共4页
Journal of Clinical Rehabilitative Tissue Engineering Research
